Competitor Shortages Allow Amphastar To Deliver ‘Strongest Quarter Yet’
Pending Launches Expected To Drive Future Growth
After shortages at competitor companies opened up gaps in the market Amphastar was able to step in to fill the void, leading to its most successful quarter yet with net revenues of $135m.
You may also be interested in...
Amphastar Receives FDA Approval For Regadenoson Following Solid Q1
Amphastar has become the fifth firm to receive FDA approval for generic regadenoson, but the exact launch date for the firm and its other generic competitors remains uncertain.
Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come
The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.